Ironwood Pharmaceuticals Upgraded to Outperform by Zacks (IRWD)
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Monday, Analyst RN reports. The firm currently has a $14.00 price target on the stock. Zacks‘ price objective suggests a potential upside of 23.89% from the company’s current price.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 1.91% on Monday, hitting $11.30. 1,222,332 shares of the company’s stock traded hands. Ironwood Pharmaceuticals has a 52-week low of $9.83 and a 52-week high of $19.67. The stock’s 50-day moving average is $12.05 and its 200-day moving average is $13.36. The company’s market cap is $1.282 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.13. The company had revenue of $9.70 million for the quarter, compared to the consensus estimate of $6.32 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. The company’s revenue for the quarter was down 33.6% on a year-over-year basis.
Several other analysts have also recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Ironwood Pharmaceuticals in a research note to investors on Monday, September 23rd. They set a “market perform” rating on the stock. Separately, analysts at BMO Capital Markets initiated coverage on shares of Ironwood Pharmaceuticals in a research note to investors on Monday, September 23rd. They set a “market perform” rating and a $15.00 price target on the stock. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Ironwood Pharmaceuticals in a research note to investors on Tuesday, September 17th. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.22.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.